Health & Fitness
Health and Fitness
Health and Fitness
Fri, October 28, 2011
[ Fri, Oct 28th 2011
] - Market Wire
[ Fri, Oct 28th 2011
] - Market Wire
[ Fri, Oct 28th 2011
] - Market Wire
[ Fri, Oct 28th 2011
] - Market Wire
[ Fri, Oct 28th 2011
] - Market Wire
[ Fri, Oct 28th 2011
] - Market Wire
[ Fri, Oct 28th 2011
] - Market Wire
[ Fri, Oct 28th 2011
] - Market Wire
[ Fri, Oct 28th 2011
] - Market Wire
Thu, October 27, 2011
[ Thu, Oct 27th 2011
] - Market Wire
[ Thu, Oct 27th 2011
] - Market Wire
[ Thu, Oct 27th 2011
] - Market Wire
[ Thu, Oct 27th 2011
] - Market Wire
[ Thu, Oct 27th 2011
] - Market Wire
[ Thu, Oct 27th 2011
] - Market Wire
[ Thu, Oct 27th 2011
] - Market Wire
[ Thu, Oct 27th 2011
] - Market Wire
[ Thu, Oct 27th 2011
] - Market Wire
[ Thu, Oct 27th 2011
] - Market Wire
[ Thu, Oct 27th 2011
] - Market Wire
[ Thu, Oct 27th 2011
] - Market Wire
[ Thu, Oct 27th 2011
] - Market Wire
[ Thu, Oct 27th 2011
] - Market Wire
[ Thu, Oct 27th 2011
] - Market Wire
[ Thu, Oct 27th 2011
] - Market Wire
[ Thu, Oct 27th 2011
] - Market Wire
Biogen Idec y Portola Pharmaceuticals anuncian colaboracin global para el programa Syk oral para el tratamiento de enfermedades
WESTON, Mass. & SOUTH SAN FRANCISCO, California--([ BUSINESS WIRE ])--[ Biogen Idec ] (NASDAQ: BIIB) y [ Portola Pharmaceuticals, Inc. ] han anunciado que han firmado un acuerdo de colaboracin y licencia mundial por el que ambas empresas desarrollarn y comercializarn inhibidores oral nuevos muy selectivos Syk para el tratamiento de varias enfermedades autoinmunes e inflamatorias, incluidas la artritis reumatoide y el lupus sistmico eritematoso.
El comunicado en el idioma original, es la versin oficial y autorizada del mismo. La traduccin es solamente un medio de ayuda ydeber sercomparada con el texto en idioma original, que es la nica versin del texto que tendr validez legal.
Contributing Sources
